Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst

NodeGuardian · 2026-03-24T02:18:34+00:00

Viatris Inc. and Opus Genetics completed a Phase 3 trial for Nyxol, aimed at improving vision in low-light conditions post-refractive surgery. While reducing development risk, market reactions depend on forthcoming efficacy and safety data, which could impact revenue and valuations.

NodeGuardian

2026-03-24 02:18:34

Abstract generation in progress

Viatris Inc. (VTRS) and Opus Genetics, Inc. (IRD) announced the completion of a Phase 3 clinical trial for Nyxol (0.75% phentolamine ophthalmic solution), an eye drop designed to improve low-light and night vision for patients who have visual disturbances after refractive surgery. The trial’s completion reduces development risk, but market reaction for involved companies will likely remain muted until the efficacy and safety data are publicly released. Positive results could create a new revenue stream for Viatris in specialty eye care and significantly impact Opus Genetics’ valuation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes